Bio Fund Iv L.P. Ah Acquires 1,100,000 Shares of Braveheart Bio (NASDAQ:BRVE) Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) major shareholder Bio Fund Iv L.P. Ah purchased 1,100,000 shares of the company’s stock in a transaction on Friday, August 7th. The shares were bought at an average price of $18.00 per share, with a total value of $19,800,000.00. Following the completion of the transaction, the insider owned 10,232,420 shares of the company’s stock, valued at approximately $184,183,560. The trade was a 12.05% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Braveheart Bio Price Performance

Shares of Braveheart Bio stock traded down $2.52 on Tuesday, reaching $25.01. The company had a trading volume of 724,651 shares, compared to its average volume of 569,084. Braveheart Bio, Inc. has a 52-week low of $24.61 and a 52-week high of $32.00.

About Braveheart Bio

We are a clinical?stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB?1893, is a next-generation oral small?molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non?obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.